The Food and Drug Administration granted Breakthrough Therapy Designation to Insmed Inc.’s (Nasdaq: INSM) nontuberculous mycobacterial lung disease treatment Arikayce/Arikace. Shares of the biopharmaceutical leaped $4.83 to $17.30.
FDA grants designation to Insmed
June 18, 2014 at 06:13 AM EDT
